An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer

详细信息    查看全文

• 作者：Luhua Wang ; Yi-Long Wu ; Shun Lu ; Lei Deng ; Myung-Ju Ahn ; Feng-Ming Hsu ; Neill Iscoe ; Anwar Hossain ; Tarun Puri ; Pinghai Zhang and Mauro Orlando
• 刊名：Asia-Pacific Journal of Clinical Oncology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：12
• 期：4
• 页码：380-387
• 全文大小：464K
• ISSN：1743-7563

文摘

PROCLAIM, a phase III trial of patients with nonsquamous non–small cell lung cancer comparing concurrent pemetrexed-cisplatin and thoracic radiation therapy followed by consolidation pemetrexed, did not meet its primary endpoint of superior overall survival versus etoposide-cisplatin and thoracic radiation therapy followed by a consolidation platinum doublet of choice. The results from an East Asian subgroup analysis are presented here.